Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIOxHEAL
- Development stage
- Phase 3
- Lead developer
- Applied Biologics
- Administration
- Topical
01
Overview
BIOxHEAL is an investigational human amniotic membrane-derived biologic therapy being developed by Applied Biologics for the treatment of chronic wounds, including nonhealing diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. Unlike passive wound covers, BIOxHEAL is designed as an active biologic therapy that works at the cellular and molecular levels to stimulate tissue regeneration, improve vascularization, and enhance the body's natural healing response. It is manufactured through a controlled, pharmaceutical-grade process to ensure consistent biologic activity and is being developed under the FDA Biologics License Application (BLA) pathway (Section 351 of the Public Health Service Act). BIOxHEAL is administered topically as a short-course adjunct to standard wound care.
- Brand names
- BIOxHEAL
Beyond the preview
Go deeper on BIOxHEAL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIOxHEAL.